Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone44-20-7062-2777
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees47
Next Earnings DateN/A
OptionableNot Optionable
Nightstar Therapeutics (NASDAQ:NITE) Frequently Asked Questions
What is Nightstar Therapeutics' stock symbol?
Nightstar Therapeutics trades on the NASDAQ under the ticker symbol "NITE."
How were Nightstar Therapeutics' earnings last quarter?
Nightstar Therapeutics PLC (NASDAQ:NITE) announced its earnings results on Tuesday, November, 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.13. View Nightstar Therapeutics' Earnings History.
What price target have analysts set for NITE?
9 analysts have issued 12-month price objectives for Nightstar Therapeutics' shares. Their predictions range from $25.18 to $26.00. On average, they expect Nightstar Therapeutics' share price to reach $25.53 in the next year. View Analyst Price Targets for Nightstar Therapeutics.
What is the consensus analysts' recommendation for Nightstar Therapeutics?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nightstar Therapeutics in the last year. There are currently 8 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Nightstar Therapeutics.
What are Wall Street analysts saying about Nightstar Therapeutics stock?
Here are some recent quotes from research analysts about Nightstar Therapeutics stock:
- 1. According to Zacks Investment Research, "Nightstar Therapeutics Limited is a clinical-stage gene therapy company. It focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases including choroideremia, X-linked retinitis pigmentosa and Best vitelliform macular dystrophy. The company operates primarily in North America and Europe. Nightstar Therapeutics Limited is based in LONDON, United Kingdom. " (5/7/2019)
- 2. Cantor Fitzgerald analysts commented, ": We are reiterating our Overweight rating and $42/share price target on Nightstar Therapeutics. This morning, Spark (N) announced a definitive agreement to be acquired by Roche (RHHBY, NC) for $4.8 billion, or $114.50/share (a 122% premium). While we believe the primary driver of the acquisition was Spark’s hemophilia A program, we have observed a trend in late- stage gene therapy company acquisitions. Given that Nightstar is one of the furthest along with a Phase 3 trial reading out next year, we believe the company deserves a seat at the table for acquisition talks and interest from pharma." (2/26/2019)
Has Nightstar Therapeutics been receiving favorable news coverage?
News stories about NITE stock have trended extremely negative this week, InfoTrie Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Nightstar Therapeutics earned a media sentiment score of -4.3 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Nightstar Therapeutics.
Who are some of Nightstar Therapeutics' key competitors?
Some companies that are related to Nightstar Therapeutics include BioNTech (BNTX), Iovance Biotherapeutics (IOVA), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Crispr Therapeutics (CRSP), Regenxbio (RGNX), Momenta Pharmaceuticals (MNTA), Denali Therapeutics (DNLI), Coherus Biosciences (CHRS), Audentes Therapeutics (BOLD), Orchard Therapeutics (ORTX), Editas Medicine (EDIT), Alector (ALEC), Sangamo Therapeutics (SGMO) and Fate Therapeutics (FATE).
What other stocks do shareholders of Nightstar Therapeutics own?
Who are Nightstar Therapeutics' key executives?
Nightstar Therapeutics' management team includes the folowing people:
- Mr. David Fellows, CEO & Director (Age 62)
- Mr. Senthil Vel Sundaram, Chief Financial Officer (Age 41)
- Dr. Gregory Scott Robinson, Chief Scientific Officer (Age 60)
- Brian Luque, Sr. Mang. of Investor Relations
- Mr. Seokho Bryan Yoon Esq., Gen. Counsel & Sec. (Age 40)
When did Nightstar Therapeutics IPO?
(NITE) raised $76 million in an initial public offering on Thursday, September 28th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and Chardan were co-managers.
How big of a company is Nightstar Therapeutics?
Nightstar Therapeutics has a market capitalization of $0.00. The company earns $-36,860,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Nightstar Therapeutics employs 47 workers across the globe.View Additional Information About Nightstar Therapeutics.
What is Nightstar Therapeutics' official website?
How can I contact Nightstar Therapeutics?
Nightstar Therapeutics' mailing address is 10 MIDFORD PLACE 2ND FLOOR, LONDON X0, W1T5BJ. The company can be reached via phone at 44-20-7062-2777 or via email at [email protected]
MarketBeat Community Rating for Nightstar Therapeutics (NASDAQ NITE)
MarketBeat's community ratings are surveys of what our community members think about Nightstar Therapeutics and other stocks. Vote "Outperform" if you believe NITE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NITE will underperform the S&P 500 over the long term. You may vote once every thirty days.
